Across TCGA pan-cancer cohorts, THAP7 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated THAP7 data layer compared with 29 for mass-spec protein.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where higher THAP7 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated THAP7 expression acts as an unfavorable survival marker.

PRAD and ESCA are the cancer types where THAP7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: THAP7 tumor-vs-normal RNA expression · all THAP7 data types